Dietary supplementation of omega-3 fatty acids rescues fragile X phenotypes in Fmr1-Ko mice

Psychoneuroendocrinology

Volumn 49, Issue 1, 2014, Pages 119-129

  Pietropaolo, Susanna ^a,b   Goubran, Mena ^a,b   Joffre, Corinne ^b,c   Aubert, Agnes ^b,c   Lemaire Mayo, Valerie ^a,b   Crusio, Wim E ^a,b   Layé, Sophie ^b,c  

^a UMR 5287   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c NutriNeuro Bordeaux University   (France)

Author keywords

Autism; Cytokines; Dietary enrichment; Fragile X; Gene environment interactions; Neurotrophins

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CD11B ANTIGEN; CD45 ANTIGEN; FRAGILE X MENTAL RETARDATION PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; OMEGA 3 FATTY ACID; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; FMR1 PROTEIN, MOUSE; LEPTIN;

ADULT; ADULTHOOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; EMOTIONAL DISORDER; FEMALE; FRAGILE X SYNDROME; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE MODEL; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SOCIAL INTERACTION; SOCIAL RECOGNITION TEST; SPATIAL MEMORY; WEANING; WILD TYPE MOUSE; ANIMAL; BIOSYNTHESIS; BLOOD; BODY COMPOSITION; BODY WEIGHT; BRAIN; DIET THERAPY; DISEASE MODEL; DRUG EFFECTS; EATING; GENETICS; METABOLISM;

ANIMALS; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY WEIGHT; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYTOKINES; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; EATING; FATTY ACIDS, OMEGA-3; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; LEPTIN; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE;

EID: 84922416711     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2014.07.002     Document Type: Article

References (51)

1. Amminger G.P., Berger G.E., Schafer M.R., Klier C., Friedrich M.H., Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol. Psychiatry 2007, 61:551-553.
2. Ashwood P., Nguyen D.V., Hessl D., Hagerman R.J., Tassone F. Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis?. Brain Behav. Immun. 2010, 24:898-902.
3. Bakker C.E., de Diego Otero Y., Bontekoe C., Raghoe P., Luteijn T., Hoogeveen A.T., Oostra B.A., Willemsen R. Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp. Cell Res. 2000, 258:162-170.
4. Bell J.G., Miller D., MacDonald D.J., MacKinlay E.E., Dick J.R., Cheseldine S., Boyle R.M., Graham C., O'Hare A.E. The fatty acid compositions of erythrocyte and plasma polar lipids in children with autism, developmental delay or typically developing controls and the effect of fish oil intake. Br. J. Nutr. 2010, 103:1160-1167.
5. Bent S., Bertoglio K., Ashwood P., Bostrom A., Hendren R.L. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J. Autism Dev. Disord. 2011, 41:545-554.
6. Bernardet M., Crusio W.E. Fmr1 KO mice as a possible model of autistic features. Sci. World J. 2006, 6:1164-1176.
7. Castren M., Lampinen K.E., Miettinen R., Koponen E., Sipola I., Bakker C.E., Oostra B.A., Castren E. BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus. Neurobiol. Dis. 2002, 11:221-229.
8. Castren M.L., Castren E. BDNF in fragile X syndrome. Neuropharmacology 2014, 76(Pt C):729-736.
9. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
10. De Felice C., Signorini C., Durand T., Ciccoli L., Leoncini S., D'Esposito M., Filosa S., Oger C., Guy A., Bultel-Ponce V., Galano J.M., Pecorelli A., De Felice L., Valacchi G., Hayek J. Partial rescue of Rett syndrome by omega-3 polyunsaturated fatty acids (PUFAs) oil. Genes Nutr. 2012, 7:447-458.
11. Dinel A.L., Andre C., Aubert A., Ferreira G., Laye S., Castanon N. Cognitive and emotional alterations are related to hippocampal inflammation in a mouse model of metabolic syndrome. PLoS One 2011, 6:e24325.
12. Gillies D., Sinn J., Lad S.S., Leach M.J., Ross M.J. Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst. Rev. 2012, 7. CD007986.
13. Goshen I., Kreisel T., Ounallah-Saad H., Renbaum P., Zalzstein Y., Ben-Hur T., Levy-Lahad E., Yirmiya R. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 2007, 32:1106-1115.
14. Gray B., Steyn F., Davies P.S., Vitetta L. Omega-3 fatty acids: a review of the effects on adiponectin and leptin and potential implications for obesity management. Eur. J. Clin. Nutr. 2013, 67:1234-1242.
15. Hagerman R.J., Hagerman P.J. The fragile X premutation: into the phenotypic fold. Curr. Opin. Genet. Dev. 2002, 12:278-283.
16. Heinrichs S.C. Dietary omega-3 fatty acid supplementation for optimizing neuronal structure and function. Mol. Nutr. Food Res. 2010, 54:447-456.
17. Johnson M., Mansson J.E., Ostlund S., Fransson G., Areskoug B., Hjalmarsson K., Landgren M., Kadesjo B., Gillberg C. Fatty acids in ADHD: plasma profiles in a placebo-controlled study ofomega 3/6 fatty acids in children and adolescents. Atten. Defic. Hyperact. Disord. 2012, 4:199-204.
18. Kelley D.S., Rudolph I.L. Effect of individual fatty acids of omega-6 and omega-3 type on human immune status and role of eicosanoids. Nutrition 2000, 16:143-145.
19. Khandjian E.W. Biology of the fragile X mental retardation protein, an RNA-binding protein. Biochem. Cell Biol. 1999, 77:331-342.
20. Labrousse V.F., Costes L., Aubert A., Darnaudery M., Ferreira G., Amedee T., Laye S. Impaired interleukin-1beta and c-Fos expression in the hippocampus is associated with a spatial memory deficit in P2X(7) receptor-deficient mice. PLoS One 2009, 4:e6006.
21. Labrousse V.F., Nadjar A., Joffre C., Costes L., Aubert A., Gregoire S., Bretillon L., Laye S. Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One 2012, 7:e36861.
22. Lafourcade M., Larrieu T., Mato S., Duffaud A., Sepers M., Matias I., De Smedt-Peyrusse V., Labrousse V.F., Bretillon L., Matute C., Rodriguez-Puertas R., Laye S., Manzoni O.J. Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat. Neurosci. 2011, 14:345-350.
23. Lafrance V., Inoue W., Kan B., Luheshi G.N. Leptin modulates cell morphology and cytokine release in microglia. Brain Behav. Immun. 2010, 24:358-365.
24. Laye S. Polyunsaturated fatty acids, neuroinflammation and well being. Prostaglandins Leukot. Essent. Fatty Acids 2010, 82:295-303.
25. Marek D., Papin S., Ellefsen K., Niederhauser J., Isidor N., Ransijn A., Poupon L., Spertini F., Pantaleo G., Bergmann S., Beckmann J.S., Jacquemont S., Tanackovic G. Carriers of the fragile X mental retardation 1 (FMR1) premutation allele present with increased levels of cytokine IL-10. J. Neuroinflamm. 2012, 9:238.
26. Martinez-Victoria E., Yago M.D. Omega 3 polyunsaturated fatty acids and body weight. Br. J. Nutr. 2012, 107(Suppl. 2):S107-S116.
27. Meiri G., Bichovsky Y., Belmaker R.H. Omega 3 fatty acid treatment in autism. J. Child Adolesc. Psychopharmacol. 2009, 19:449-451.
28. Milte C.M., Parletta N., Buckley J.D., Coates A.M., Young R.M., Howe P.R. Increased erythrocyte eicosapentaenoic acid and docosahexaenoic acid are associated with improved attention and behavior in children with ADHD in a randomized controlled three-way crossover trial. J. Atten. Disord. 2013, 10.1177/1087054713510562.
29. Moreno-Aliaga M.J., Lorente-Cebrian S., Martinez J.A. Regulation of adipokine secretion by n-3 fatty acids. Proc. Nutr. Soc. 2010, 69:324-332.
30. Nawara M., Klapecki J., Borg K., Jurek M., Moreno S., Tryfon J., Bal J., Chelly J., Mazurczak T. Novel mutation of IL1RAPL1 gene in a nonspecific X-linked mental retardation (MRX) family. Am. J. Med. Genet. A 2008, 146A:3167-3172.
31. Oddi D., Crusio W.E., D'Amato F.R., Pietropaolo S. Monogenic mouse models of social dysfunction: implications for autism. Behav. Brain Res. 2013, 251:75-84.
32. Philofsky A., Hepburn S.L., Hayes A., Hagerman R., Rogers S.J. Linguistic and cognitive functioning and autism symptoms in young children with fragile X syndrome. Am. J. Ment. Retard. 2004, 109:208-218.
33. Pietropaolo S., Feldon J., Alleva E., Cirulli F., Yee B.K. The role of voluntary exercise in enriched rearing: a behavioral analysis. Behav. Neurosci. 2006, 120:787-803.
34. Pietropaolo S., Guilleminot A., Martin B., D'Amato F.R., Crusio W.E. Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice. PLoS One 2011, 6:e17073.
35. Poo M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci. 2001, 2:24-32.
36. Qin M., Kang J., Smith C.B. A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior. Neuroscience 2005, 135:999-1009.
37. Rao J.S., Ertley R.N., Lee H.J., DeMar J.C., Arnold J.T., Rapoport S.I., Bazinet R.P. n-3 polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism. Mol. Psychiatry 2007, 12:36-46.
38. Richardson A.J. Omega-3 fatty acids in ADHD and related neurodevelopmental disorders. Int. Rev. Psychiatry 2006, 18:155-172.
39. Rustan A.C., Nenseter M.S., Drevon C.A. Omega-3 and omega-6 fatty acids in the insulin resistance syndrome. Lipid and lipoprotein metabolism and atherosclerosis. Ann. N. Y. Acad. Sci. 1997, 827:310-326.
40. Sable P.S., Kale A.A., Joshi S.R. Prenatal omega 3 fatty acid supplementation to a micronutrient imbalanced diet protects brain neurotrophins in both the cortex and hippocampus in the adult rat offspring. Metabolism 2013, 62:1607-1622.
41. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protocols 2008, 3:1101-1108.
42. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci. Biobehav. Rev. 2000, 24:417-463.
43. The Dutch-Belgian Fragile X Consortium Dutch-Belgian Fragile X Consortium Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 1994, 78:23-33.
44. Tsiouris J.A., Brown W.T. Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy. CNS Drugs 2004, 18:687-703.
45. Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.H., Kuhl D.P., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F.P., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
46. Winarni T.I., Chonchaiya W., Sumekar T.A., Ashwood P., Morales G.M., Tassone F., Nguyen D.V., Faradz S.M., Van de Water J., Cook K., Hamlin A., Mu Y., Hagerman P.J., Hagerman R.J. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am. J. Med. Genet. A 2012, 158A:2473-2481.
47. Wu A., Ying Z., Gomez-Pinilla F. Dietary strategy to repair plasma membrane after brain trauma: implications for plasticity and cognition. Neurorehabil. Neural Repair 2014, 28:75-84.
48. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 2011, 25:181-213.
49. Young G.S., Maharaj N.J., Conquer J.A. Blood phospholipid fatty acid analysis of adults with and without attention deficit/hyperactivity disorder. Lipids 2004, 39:117-123.
50. Yuskaitis C.J., Beurel E., Jope R.S. Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochim. Biophys. Acta 2010, 1802:1006-1012.
51. Zhang W., Li P., Hu X., Zhang F., Chen J., Gao Y. Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. Front. Biosci. (Landmark Ed.) 2011, 16:2653-2670.